MarketBeat 重点介绍了 9 月份受药物批准和政策变化推动的顶级制药和医疗保健股。 MarketBeat highlights top pharmaceutical and healthcare stocks for September, driven by drug approvals and policy changes.

MarketBeat的股票筛选器突出显示九月份几股重要的药品和保健物资。 MarketBeat's stock screener highlights several key pharmaceutical and healthcare stocks for September. Eli Lilly、Pfizer、Merck、Honeywell、Thermo Fisher Science、Novo Nordisk和Amgen等制药公司在药物审批和保健政策变化的推动下交易量和业绩都很高。 In pharmaceuticals, Eli Lilly, Pfizer, Merck, Honeywell, Thermo Fisher Scientific, Novo Nordisk, and Amgen are noted for their high trading volumes and performance driven by drug approvals and healthcare policy changes. 对于更广泛的医疗保健，重点介绍了 UnitedHealth Group、Eli Lilly、Johnson & Johnson、Alphabet、Salesforce、Hims & Hers Health 和 Intuitive Surgical。 For broader healthcare, UnitedHealth Group, Eli Lilly, Johnson & Johnson, Alphabet, Salesforce, Hims & Hers Health, and Intuitive Surgical are highlighted. 这些公司提供多种服务,包括保健计划、客户关系管理技术、远程保健以及外科手术系统。 These companies offer diverse services including health plans, CRM technology, telehealth, and surgical systems. 这些股票的投资者可以受益于保健行业的增长,尽管他们必须管理研发失败等风险。 Investors in these stocks can benefit from healthcare industry growth, though they must manage risks like R&D failures.